Articles
and Reviews
This page provides links
to selected abstracts, full-text
articles, and other recommended reading for healthcare
professionals involved
with breast and
cervical cancer screening and diagnosis. New topics will be added regularly. Please check back often.
All links lead to external websites and
open in a new browser window. Please close the window
to return to this page.
Breast Cancer:
|
|
|
Clinical
Breast Exam
Barton MB, Harris R, Fletcher
SW. (1999). The rational clinical examination.
Does this patient have breast cancer? The screening
clinical breast examination: should it be done?
How? JAMA, Oct;282(13):1270-80. Abstract
Benincasa TA, King ES, Rimer BK, Bloom HS, Balshem A,
James J, et al. (1996). Results of an office-based training
program in clinical breast examination for primary care
physicians. J Cancer Educ, Spring;11(1):25-31. Abstract
Bobo JK, Lee NC, Thames SF. (2000). Findings
from 752,081 clinical breast examinations reported
to a national screening program from 1995 through 1998. J
Natl Cancer Inst, Jun;92(12):971-6. Abstract
Chalabian J, Dunnington G. (1998). Do our current
assessments assure competency in clinical breast evaluation
skills? Am J Surg, Jun;175(6):497-502. Abstract
Day, N. (2008). The need for performance and standardization of the best clinical breast exam. The Journal for Nurse Practitioners, 4(5): 342-349. Abstract
Fletcher SW, O'Malley MS, Bunce LA. (1985). Physicians'
abilities to detect lumps in silicone breast models. JAMA, Apr;253(15):2224-8. Abstract
Foster RS Jr, Worden JK, Costanza MC,
Solomon LJ. (1992). Clinical breast examination and
breast self-examination. Past and present effect on
breast cancer survival. Cancer,
Apr;69(7 Suppl):1992-8. Review. Abstract
Goodson III, WH, (1996). Topics in primary
care medicine: clinical breast examination. West
J Med, 164:355-358. Full
Text (pdf)
Goodson, III, WH, Moore, II, DH. (2002).
Overall clinical breast examination as a factor in
delayed diagnosis of breast cancer. Arch
Surg, 137:1152-1156. Abstract Full
Text
McDonald S, Saslow D, Alciati MH. (2004). Performance
and reporting of clinical breast examination: a review
of the literature. CA Cancer
J Clin, Nov-Dec;54(6):345-61. Review. Abstract
Miller AB, To T, Baines CJ, Wall C. (2000). Canadian
National Breast Screening Study-2: 13-year results
of a randomized trial in women aged 50-59 years.
J Natl Cancer Inst,
Sep;92(18):1490-9. Abstract
Pennypacker HS, Naylor L, Sander AA, Goldstein MK.
(1999). Why can't we do better breast examinations? Nurse
Pract Forum, Sep;10(3):122-8. Abstract
Saslow D, Hannan J, Osuch J, Alciati, MH, Baines,
C, Barton, M, et al. (2004). Clinical breast examination:
practical recommendations for optimizing performance
and reporting.CA Cancer J Clin,
Nov-Dec;54(6):327-44. Abstract
Wallace AE, MacKenzie TA, Weeks WB. (2006). Women's primary care providers and breast cancer screening: who's following the guidelines? Am J Obstet Gynecol, Mar;194(3):744-8. Abstract
Top of page
Hormone
Replacement Therapy
Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer
RD, Gilligan MA, Walsh BW, Chen C, McTiernan A; Women's
Health Initiative Investigators (2008). Estrogen plus
progestin and breast cancer detection by means of mammography
and breast biopsy. Arch Intern
Med, Feb 25;168(4):370-7;
quiz 345. Erratum in: Arch Intern Med. 2008 May 12;168(9):935.
Gillian, Mary Ann [corrected to Gilligan, Mary Ann]. Abstract
Top of page
Cervical Cancer:
Human
Papillomavirus (HPV)
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson
H, Unger ER; Centers for Disease Control and Prevention
(CDC); Advisory Committee on Immunization Practices (ACIP).
(2007). Quadrivalent Human Papillomavirus Vaccine: Recommendations
of the Advisory Committee on Immunization Practices (ACIP). MMWR
Recomm Rep, Mar 23;56(RR-2):1-24.
Genital human papillomavirus (HPV) is the most common
sexually transmitted infection in the United States.
Although the majority of infections cause no symptoms
and are self-limited, infection with certain HPV types
is considered necessary for the development of cervical
cancer. In June 2006, the quadrivalent HPV vaccine
types 6, 11, 16, 18 was licensed for use among females,
ages 9 to 26 years, for prevention of vaccine HPV-type-related
cervical cancer, cervical cancer precursors, vaginal
and vulvar cancer precursors, and anogental warts.
In March, 2007, the Advisory Committee on Immunization
Practices (ACIP) published its first statement on the
use of this vaccine..
Read the full
text report at the Centers for Disease Control
and Prevention (CDC) website.
Top of page
Reviewed: December 20, 2011
|
